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Abstract
Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug.
Since evidence shows a strong clinical and genetic overlap between depression and bipolar disorder, we investigated whether
a polygenic susceptibility to major depression is associated with response to lithium treatment in patients with BD. Weighted
polygenic scores (PGSs) were computed for major depression (MD) at different GWAS p value thresholds using genetic data
obtained from 2586 bipolar patients who received lithium treatment and took part in the Consortium on Lithium Genetics
(ConLi+Gen) study. Summary statistics from genome-wide association studies in MD (135,458 cases and 344,901 controls)
from the Psychiatric Genomics Consortium (PGC) were used for PGS weighting. Response to lithium treatment was defined
by continuous scores and categorical outcome (responders versus non-responders) using measurements on the Alda scale.
Associations between PGSs of MD and lithium treatment response were assessed using a linear and binary logistic
regression modeling for the continuous and categorical outcomes, respectively. The analysis was performed for the entire
cohort, and for European and Asian sub-samples. The PGSs for MD were significantly associated with lithium treatment
response in multi-ethnic, European or Asian populations, at various p value thresholds. Bipolar patients with a low polygenic
load for MD were more likely to respond well to lithium, compared to those patients with high polygenic load [lowest vs
highest PGS quartiles, multi-ethnic sample: OR= 1.54 (95% CI: 1.18–2.01) and European sample: OR= 1.75 (95% CI:
1.30–2.36)]. While our analysis in the Asian sample found equivalent effect size in the same direction: OR= 1.71 (95% CI:
0.61–4.90), this was not statistically significant. Using PGS decile comparison, we found a similar trend of association
between a high genetic loading for MD and lower response to lithium. Our findings underscore the genetic contribution to
lithium response in BD and support the emerging concept of a lithium-responsive biotype in BD.
Introduction
Bipolar disorder (BD) is a chronic and severe psychiatric ill-
ness characterized by episodic, abnormal manic and depressive
mood states. An estimated 48.8 million people are affected by
BD globally [1]. The disorder accounts for 9.9 million years of
life lived with disability worldwide, and substantially increases
all-cause mortality and risk of suicide [1, 2].
Amongst available treatment options, lithium is regarded
as a gold standard by several clinical guidelines [3, 4].
Lithium uniquely protects against both manic and depressive
illness phases, has demonstrated protective effects against
suicide [5–7], and is particularly effective in preventing
rehospitalization [8]. However, not all patients with BD
fully benefit from lithium and only about 30% show full
response to the drug [5–7]. In current psychiatric practice,
no biological or clinical markers exist that could reliably
predict responsiveness to lithium [9], and prescribing
cannot be targeted to patients who benefit most while
avoiding side effects and sub-optimal treatment for poor
responders [10–13].
In order to develop objective response markers and to
move forward towards personalized prescribing of lithium
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for BD patients, a better understanding of the biological
mechanisms underlying lithium response is urgently
required. Recent genome-wide association studies (GWAS)
carried out by our International Consortium on Lithium
Genetics (ConLi+Gen) [5] and others [14, 15] have indi-
cated that genetic variation could be an important mediator
of response to long-term lithium treatment response in BD
patients. In addition, we have recently demonstrated that
high genetic loading for schizophrenia (SCZ) risk variants
in people with BD decreases the likelihood of favorable
response to lithium [16], suggesting that polygenic score
(PGS) analysis of mental and physical traits could yield
important information on the genetic architecture of BD
phenotypes [17–19].
BD and MD show 47% genetic overlap [20–22], and
shared risk genes and biological pathways have been
described [21, 23, 24]. Lithium can be effective as an
augmentation strategy in MD patients who have experi-
enced an insufficient response to first-line antidepressants
[25, 26] and is protective against further MD episodes after
symptom remission has been achieved [27]. Moreover, a
large observational study based on the Finnish registry
showed that lithium is the most effective agent preventing
rehospitalization in MD [27].
On the other hand, in BD, lithium is more effective in
preventing manic than depressive episodes [28, 29], leading
to the notion that better lithium responders might be more
likely to experience manic predominant polarity, as opposed
to depressive predominant polarity [30]. In support of this
view, one study found that excellent lithium responders
were characterized by a manic but not depressive polarity of
the index episode [31]. Another study described an episodic
illness pattern of ‘mania-depression-interval’ as a predictor
for a good response, whereas a ‘depression-mania-interval’
predicted poorer outcomes [32]. Inter-episode residual
mood symptoms, as opposed to full remission [6, 7, 33], a
rapid cycling pattern [32, 33], and a history of mixed epi-
sodes [34, 35] have also been described as predictors of
poor response.
On the background of these complex interactions between
BD, MD, and lithium treatment, we asked whether BD
patients with a high genetic susceptibility for major depres-
sion, expressed by their PGS, would respond better or worse
to lithium than BD patients with a low genetic loading [36].
Methods and materials
Discovery GWAS summary dataset
The polygenic score for this study was computed using
individual genetic data from the International Consortium
on Lithium Genetics (ConLi+Gen) [5], and GWAS
summary statistics for MD from the Psychiatric Genomics
Consortium (PGC) [36].
The summary GWAS for MD was produced from a
meta-analysis of 9.6 million SNPs (PGC; http://www.med.
unc.edu/pgc/), obtained from 7 cohorts (deCODE, Genera-
tion Scotland, GERA, iPSYCH, UK Biobank, PGC29 and
23andMe) containing 135,458 MD cases and 344,901
healthy controls [36].
Target study sample
For the PGS analysis, clinical data on lithium treatment
response and genetic information were obtained from the
International Consortium on Lithium Genetics (ConLi
+Gen; www.ConLiGen.org) for n= 2586 patients, including
23 patients in the replication sample [3, 5, 16]. A series of
quality control procedures were implemented on the geno-
type data before and after imputation as described below.
Target outcome
Lithium treatment response was assessed using the vali-
dated “Retrospective Criteria of Long-Term Treatment
Response in Research Subjects with Bipolar Disorder”
scale, also known as the Alda scale [7, 37, 38]. This scale
quantifies symptom improvement over the course of
treatment (A score, range 0–10), which is then weighted
against five criteria (B score) that assess the quality of
evidence for the response score [5], to arrive at a total Alda
score. For dichotomized assessment of treatment response,
patients with a total score of 7 or higher were categorized
as “good responders”, and the remainder were categorized
as poor responders [5, 38]. For continuous assessment of
treatment response, Alda A scores were used [39]. In
addition to the Alda scale scores, information on covariates
such as age and gender was collected, as described in
detail elsewhere [5].
Genotyping and quality control
The genome-wide genotypes, as well as clinical and
demographic data, were collected by 22 participating
sites. Quality control (QC) procedures were implemented
on the genotype data using PLINK, version 1.09 prior to
imputation [40]. Samples with low genotype rates <95%,
sex inconsistencies (based on X-chromosome hetero-
zygosity), and one of a pair of genetically related indivi-
duals were excluded. SNPs were excluded based on the
following criteria: a poor genotyping rate (<95%), strand
ambiguity (A/T and C/G SNPs), a low minor allele fre-
quency (MAF < 1%), or those deviated from genotype
frequency expectations under the Hardy–Weinberg Equi-
librium (p < 10–6).
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Imputation
The genotype data passing QC were imputed on the Michi-
gan server [41] (https://imputationserver.sph.umich.edu)
separately for each genotype platform using reference data
from the 1000 Genomes Project Phase 3 (Version 5). The
European reference panel was used for all the samples
except for those from Japan and Taiwan, for which an East
Asian reference population data was used. After excluding
low-frequency SNPs (MAF < 10%); low-quality variants
(imputation INFO < 0.9); and indels, the imputed dosages
were converted to best-guess genotypes. The subsequent
polygenic analyses were performed using these best-guess
genotypes.
Statistical analyses
Polygenic score (PGS) association analysis
PGSs were calculated using the approach previously
described by the International Schizophrenia Consortium
[42]. Prior to the PGS computation, independent SNPs
were identified through a clumping procedure. Quality-
controlled SNPs were clumped for linkage disequilibrium
based on GWAS association p value informed clumping at
r2 = 0.1 within a 250-kilobase window to create an SNP-
set in linkage equilibrium using PLINK software, version
1.09 run on Linux (plink --clump-p1 1 --clump-p2 1
--clump-r2 0.1 --clump-kb 250). PGSs of MD were cal-
culated for each patient in the ConLi+Gen sample at ten p
value thresholds (<1 × 10−4, <1 × 10−3, <0.01, <0.05,
<0.1, <0.2, <0.3, <0.4, <0.5, <1). For a patient, a PGS was
calculated at each p value threshold (PT) as the sum of
allelic counts (from 0 to 2) for the reference alleles across
independent SNPs on a genome-wide scale weighted by
their effect sizes estimated as beta or log10 (odds ratio),
obtained from previously published GWASs of MD [36].
Once the PGSs were constructed, a binary logistic
regression model was applied for the binary outcome
(lithium response versus non-response) and a linear
regression modeling was implemented for the continuous
outcome (Alda score on subscale A) to evaluate the
association of the PGSs for MD with lithium treatment
response at each PT. Using the PGS at the most optimal
thresholds, we divided the study samples into quartiles and
deciles, ranging from the lowest polygenic load (1st
quartile or 1st decile) to the highest polygenic load (4th
quartile or 10th decile). Then, we compared BP patients in
the lower polygenic load quartiles (1st–3rd quartiles or
1st–9th deciles) with patients in the highest polygenic load
quartile (4th quartile or 10th decile), to quantify the effect
of MD polygenic load on lithium treatment response. The
analysis was performed for the European sample (N=
2366), Asian sample (N= 220) and all the sample com-
bined (N= 2586). Associations were considered sig-
nificant at p < 0.05 after adjusting for covariates.
The PGS association analyses were adjusted for the
covariates age, gender, genotyping platform, a polygenic
score for schizophrenia [16], a polygenic score for bipolar
disorder [43], and seven principal components (PCs) in
the combined sample or five PCs in the European sample
or four PCs in the Asian sample. The PCs were computed
using a --pca command in PLINK and then the top PCs
with an eigenvalue of >2.0 were extracted and used as
covariates to correct for population stratification. The
analyses were performed using R for Statistical Comput-
ing and PLINK, version 1.09 for Linux [40]. Prediction
accuracy, the percentage of variance in lithium response
accounted for by the PGS at each PT, was estimated as the
variance explained by the full model including each PGS
and covariates minus the variance explained by the model
including only covariates.
Sensitivity analysis
To evaluate the robustness of our findings, we ran sen-
sitivity analyses using GWAS summary data from bone
traits [lumbar spine bone mineral density, femoral neck
mineral density and forearm bone mineral density] [44]
that have previously shown nonsignificant genetic cor-
relations with psychiatric disorders [45]. Once we com-
pute polygenic scores for lumbar spine bone mineral
density, femoral neck mineral density and forearm bone
mineral density, we evaluated its association with
lithium treatment response, both continuous and cate-
gorical outcomes, in the combined sample (N= 2586).
Each analysis was adjusted for covariates age, gender,
genotyping platform, polygenic score for schizophrenia
[16], polygenic score for bipolar disorder [43] and
seven PCs.
Results
Sample characteristics and lithium treatment
response rate
After QC, 2586 patients (3193 before QC) remained for
analysis. While n= 2366 were of European ancestry, the
remaining (n= 220) were of Asian ancestry. In all, 704
patients (27.2%) responded optimally to lithium treatment
(total Alda score ≥7). Detailed sample and demographics
details have been described previously [16]. Analysis
of the correlation between the PGSs for MD and the self-
reported number of depressive episodes available for a
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subset of the ConLi+Gen sample (N= 1140) showed a
statistically significant positive correlation, with estimates
ranging from 0.08 to 0.12, suggesting that the PGS for
MD may be an approximation to a more severe depressive
phenotype in BD (Supplementary Fig. 1).
The polygenic score for MD is inversely associated
with lithium treatment response in BD
Statistically significant associations were found at various
p value thresholds between the PGSs for MD and lithium
treatment response. In the combined multi-ethnic sample,
the strongest association were found at PT < 5 × 10
−2; p <
0.001, R2= 0.8% with the continuous outcome (Alda A
score) and p < 0.001, R2= 0.7% with the categorical out-
come (total Alda score ≥7) (Fig. 1a).
In European ancestry patients, the PGS at most of the
tested p value thresholds showed significant associations
of MD PGS with lithium response across continuous and
dichotomized outcomes. Strongest associations were
found at PT < 5 × 10
−2; p < 0.001, R2 = 0.7% with the
continuous outcome and p < 0.001, R2= 0.9% with the
categorical outcome (Fig. 1b). However, in the Asian
subsample, the association of the PGS for MD and lithium
treatment response was less robust and marginal asso-
ciations were found only with the continuous outcome at
PT < 1 × 10
−2 (p= 0.034, R2 = 0.85%) and PT < 5 × 10−2
(p= 0.042, R2= 0.75%) (Fig. 1c). Using PRSice2 soft-
ware, we found consistent results of association between
the PGSs for MD and lithium treatment response [46]
(Supplementary Fig. 2A–C). After adjusting for multiple
testing using the Bonferroni method [47], associations
remained statistically significant in the muti-ethnic and
European sample, but not in the Asian sample (Supple-
mentary Table 1). Beta coefficients for all associations
were negative, indicating that high genetic loadings for
MD are associated with poorer response to lithium in BD.
To further evaluate the impact of MD PGS on lithium
treatment response, we divided the study population
into quartiles and deciles based on their polygenic loading
for MD. As shown in Fig. 2 and Table 1, BD patients
who carry a lower polygenic load (1st quartile or 1st
decile) for MD have higher odds of favorable lithium
treatment response, compared to patients carrying a high
polygenic load (4th quartile or 10th decile). In the com-
bined sample, the odds ratio (OR) of favorable response
for patients in the 1st quartile compared with those in the
4th quartile was 1.54 (95% CI: 1.18–2.01) and the OR
of patients in 1st decile compared to the 10th decile
was 1.49 (95% CI: 0.97–2.31). Stratified analysis by
ethnicity found a stronger association in the European
sample than the Asian sample (Table 1, Fig. 2 & Sup-
plementary Fig. 3).
Sensitivity analysis
To ensure the robustness of our findings, we performed a
sensitivity analysis and found no significant association
between the polygenic scores for lumbar spine bone mineral
density, femoral neck mineral density or forearm bone
mineral density and lithium treatment response in bipolar
patients, p > 0.05 for all polygenic score association tests at
different p value thresholds (Supplementary Fig. 4A–C).
Discussion
Our study represents the first direct molecular evidence of an
association between a genetic predisposition for major
depression and poorer response to lithium treatment in
patients with BD. Using PGS analyses of genetic variants
related to MD, we found that BD patients with low genetic
loading for these variants were about 1.5 times more likely
to have favorable long-term outcomes following lithium
treatment compared to BD patients with high MD genetic
loading. Higher MD PGSs were associated with a higher
number of reported life-time depressive episodes. Analyses
following stratification of our sample into European and
Asian ancestries indicated that these associations were par-
ticularly robust in the European subsample. Adjustment for
the potential effects of psychiatric traits that show genetic
overlap with MD (SCZ, BD), and sensitivity analyses with
medical traits that are unrelated to psychiatric disorders [44]
underscored the overall robustness of our findings.
Our findings could form part of a genetic explanation for
the previously described clinical observations in relation to
mania, depression and lithium response in BD [6, 7, 28–35]
and supports the notion that better lithium responsiveness
could be associated with a ‘core’ bipolar phenotype in
the Kraepelinian form of manic depression [35, 48],
characterized by a predominant mania-depression-interval
(MDI) sequence pattern [49, 50]. The fact that such a
phenotype is complex and difficult to clinically identify
is exemplified by the lack of meta-analytic evidence
for a more straightforward association between lithium
response and mania over depression dominance in BD [50].
Similarly, previous family studies found no association
between a family psychiatric history of MD and poorer
lithium response in BD [51].
Together with the previously reported inverse association
of lithium response and schizophrenia PGS [16], in the same
cohort, our finding suggests that the presence of psychiatric
co-morbid genetic traits in BD diminishes the likelihood of
optimal treatment response to lithium. Given the substantial
overlap between schizophrenia- and MD risk alleles [43], the
possibility that these effects are driven by similar molecular
mechanisms warrants further clarification in future studies.
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In addition to its effects in BD, lithium’s effectiveness as an
adjunct antidepressant treatment for people with treatment-
resistant MD is well established [52–58], and lithium is a first-
line treatment for BD type 2 that shows a substantial genetic
overlap with MD [59]. Therefore, our finding raises the
intriguing possibility that lithium possesses specific anti-
depressant mechanisms of action that are different from the
mechanisms conferring long-term treatment response in BD.
Fig. 1 The association of PGS
for major depression (MD)
and lithium treatment
response at different GWAS
p value thresholds. The y-axis
refers to the percentage of
variance in treatment response to
lithium accounted for by the
PGSs for MD at particular
p value thresholds. On the
x-axis, are the GWAS p value
thresholds used to select single-
nucleotide polymorphisms for
the PGSs. On the top of each bar
are the p values for the
association between the PGSs
for MD and lithium treatment
response. Beta coefficients (not
shown) were negative for all
associations, indicating an
inverse effect of MD PGS on
lithium response.
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Our finding of a more robust effect of the MD PGS
association with lithium response in European compared
to Asian patients is interesting but needs to be interpreted
with caution. First, our Asian subsample was small (n=
220) and may not have been powered sufficiently to detect
more consistent effects. Second, the polygenic basis of
MD in East Asian and European populations is only
partially shared with reported trans-ancestry genetic cor-
relation of 0.33–0.41 [60]. The projection of MD risk
alleles obtained from the global PGC study onto the Asian
ConLi+Gen cohort for PGS analysis may, therefore, be
less precise and underestimate the true MD PGS effect. It
Fig. 2 Odds ratios (ORs) for
favorable treatment response
to lithium in patients with BD.
ORs are derived by comparing
BD patients with the low major
depression (MD) polygenic load
deciles (1st–9th) with patients
with the highest MD polygenic
load (10th decile), estimated at
the most significant p value
thresholds (n= 2586).
Table 1 Odds ratios of favorable lithium treatment response in patients with BD—comparing the response status of patients in the low polygenic
score (PGS) quartile or decile for MD with patients with the highest polygenic load (4th quartile or 10th decile).














1st: lowest score 1.50(1.17–1.92) 1.54(1.18–2.01) 1.86(1.41–2.47) 1.75(1.30–2.36) 1.43(0.55–3.79) 1.71(0.61–4.90)
2nd 1.45(1.13–1.86) 1.46(1.12–1.90) 1.81(1.37–2.40) 1.77(1.31–2.38) 1.54(0.60–4.04) 1.74(0.64–4.85)
3rd 1.16(0.90–1.49) 1.12(0.85–1.47) 1.25(0.94–1.66) 1.21(0.89–1.64) 0.63(0.21–1.81) 0.55(0.17–1.66)
4th: highest score 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Decile
1st: lowest score 1.50(1.00–2.27) 1.49(0.97–2.31) 1.92(1.23–2.99) 1.74(1.08–2.81) 1.77(0.40–8.52) 2.12(0.41–12.13)
2nd 2.06(1.39–3.09) 2.09(1.38–3.20) 2.10(1.35–3.28) 1.98(1.24–3.18) 1.25(0.27–6.08) 1.50(0.28–8.61)
3rd 1.76(1.18–2.64) 1.68(1.10–2.59) 1.90(1.22–2.96) 1.65(1.03–2.66) 1.62(0.37–7.73) 2.26(0.46–12.55)
4th 1.84(1.23–2.75) 1.80(1.18–2.77) 1.77(1.14–2.77) 1.72(1.08–2.78) 1.25(0.27–6.08) 1.68(0.33–9.44)
5th 1.49(1.00–2.25) 1.43(0.93–2.20) 1.92(1.23–2.99) 1.80(1.13–2.90) 1.25(0.27–6.08) 1.40(0.28–7.49)
6th 1.38(0.92–2.10) 1.23(0.80–1.92) 1.00(0.63–1.59) 0.91(0.56–1.50) 0.41(0.05–2.43) 0.43(0.05–2.87)
7th 1.39(0.92–2.10) 1.39(0.90–2.15) 1.65(1.06–2.58) 1.65(1.03–2.66) 0.93(0.18–4.68) 0.95(0.17–5.46)
8th 1.30(0.86–1.97) 1.19(0.77–1.85) 1.36(0.87–2.14) 1.19(0.74–1.94) 0.41(0.05–2.43) 0.40(0.04–2.74)
9th 1.25(0.82–1.90) 1.17(0.75–1.81) 0.92(0.57–1.47) 0.91(0.56–1.50) 1.25(0.27–6.08) 0.61(0.12–3.34)
10th: highest score 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
The references (4th quartile and 10th decile) are the PGSs categories with the highest polygenic load for MD at the most significant threshold.
aAdjusted for the covariates age, gender, genotyping platform, PGS for schizophrenia [16], PGS for bipolar disorder [43], and seven principal
components (PCs) in the combined sample or five PCs in the European sample or four PCs in the Asian sample. OR odds ratio.
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is notable that ethnic differences with regards to lithium
response have not been studied extensively and are not
supported by a smaller previous study [61].
The main limitation of our study is that PGSs for MD
explain only a small proportion of the variance in lithium
treatment response (<1%), and on their own have no utility
as clinical tests. However, since we detected significant
effects in our relatively small sample, it is likely that in the
future increased sample sizes will further improve the pre-
dictive power of PGSs [62]. Further, the current version of
the Alda scale assesses only overall lithium efficacy but not
effects specific to predominant illness polarity or episode
sequence pattern. Availability and incorporation of such
information would have refined our results. While our
findings, in isolation, are not yet ripe for clinical applica-
tions, they could serve as a component of multimodal pre-
diction models incorporating clinical and other biological
data. The development of such models and the demonstra-
tion of their potential clinical utility in prospective study
designs are beyond the scope of the current investigation
but need to be attempted to translate our research findings
into actionable clinical applications.
In conclusion, we demonstrated that high genetic load-
ings for MD are predictive of unfavorable long-term
response to lithium in patients with BD. Our study under-
scores the potential of PGS analysis to contribute to
predictive models for medication response in psychiatry.
The results of our study support clinical observations
that have pointed to better lithium responsiveness in a BD
subtype characterized by lower psychiatric co-morbidity
and more dominant mania-related clinical features.
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